Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)

BALCHEM CORP

2024-Q2 EPS reported $1.87 revenue$473,740,000

GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
Record adjusted EBITDA $62.3M (+5.0% YoY); cash from ops $45.0M; free cash flow $38.4M.
Human Nutrition & Health and Specialty Products segments post strong sales and earnings growth.
Launched Optifolin+ patented choline-enriched folate ingredient on May 20, 2024.
Repaid $35M revolving debt; net debt $202.8M; leverage ratio 0.9x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.